Abstract
The aim of this study was to evaluate the safety and efficacy of CD34+ cells in autologous peripheral blood stem cell transplantation (PBSCT) for the treatment of refractory autoimmune diseases (AD). Methods: Six cases of systemic sclerosis (SSc) with interstitial pneumonia (IP), one case of amyopathic dermatomyositis (ADM) with IP, and one case of Wegener’s granulomatosis with exophthalmous. PBSCs were mobilized with CY 4 g/m2+ G-CSF, and CD34+ cells were purified with CliniMACS. Pretransplantation conditioning consisted of CY 200 mg/kg.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
